substituted C_1-C_{20} aminoalkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_1-C_{20} haloalkyl, optionally substituted C_1-C_{20} hydroxyalkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl; each of which is optionally substituted with one or more R^Z;

each R^{3a} and R^{3b} is independently hydrogen, halogen, C_1-C_6 alkyl, -OR^{3c}, -$NR^{3c}R^{3d}$, or -$NHC(O)R^{3e}$, wherein

R^{3c} and R^{3d} are each independently hydrogen, alkyl, or PEG;

R^{3e} is alkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

or two R^{3a} or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

or one R^{3a} and one R^{3b} together with the atoms to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl; and

each R^Z is independently halogen, -CN, -OH, -OR^{Za}, -N_3, -$NR^{Za}R^{Zb}$, -$CO(O)R^{Zc}$, -$C(O)OR^{Zc}$, -$C(O)NR^{Za}R^{Zb}$, C_1-C_{10} alkyl, C_1-C_{10} haloalkyl, C_1-C_{10} heteroalkyl, C_3-C_{10} cycloalkyl, 3 to 10-membered heterocycloalkyl, phenyl, or optionally 5 to 10-membered heteroaryl; wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and


R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene; and

c) the oligomeric backbone links the first terminus and the second terminus.

[0007a] In one aspect, there is provided a transcription modulator molecule having a first terminus, a second terminus, and an oligomeric backbone moiety, or a pharmaceutically acceptable salt thereof, characterized in that:

a) the first terminus comprises a DNA-binding moiety having the structure of Formula (A-9):



Formula (A-9),

wherein:

W^1 is hydrogen, -C_1-C_6 haloalkyl, or -N=C($N(R^{1e})_2$)$_2$, wherein each R^{1e} is independently hydrogen or optionally substituted C_1-C_3 alkyl;

R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2g}, and R^{2h} are each independently hydrogen, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} aminoalkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_1-C_{20} haloalkyl, optionally substituted C_1-C_{20} hydroxyalkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl; each of which is optionally substituted with one or more R^Z;

each R^{3a} and R^{3b} is independently hydrogen, halogen, C_1-C_6 alkyl, -OR^{3c}, -$NR^{3c}R^{3d}$, or -$NHC(O)R^{3e}$, wherein

R^{3c} and R^{3d} are each independently hydrogen, alkyl, or PEG;

R^{3e} is alkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

or two R^{3a} or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

or one R^{3a} and one R^{3b} together with the atoms to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

each R^Z is independently halogen, -CN, -OH, -OR^{Za}, -N_3, -$NR^{Za}R^{Zb}$, -$CO(O)R^{Zc}$, -$C(O)OR^{Zc}$, -$C(O)NR^{Za}R^{Zb}$, -$NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, C_1-C_{10} heteroalkyl, C_3-C_{10} cycloalkyl, 3 to 10-membered heterocycloalkyl, phenyl, or optionally 5 to 10-membered heteroaryl; wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and

R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene by binding a target selected from a member of the BET (bromodomain and extra-terminal) family, CBP/p300, PCAF (P300/CBP-Associated Factor), CECR2 (cat eye syndrome chromosome region candidate 2), BRPF (bromodomain and PHD finger-containing protein), ATAD2/ATAD2B (chromatin remodeling proteins), TRIM24 (Tripartite motif-containing 24), BAZ2 (Bromodomain Adjacent to Zinc finger), or TAF1 (TBP associated factors); and

c) the oligomeric backbone links the first terminus and the second terminus.

[0007b] In another aspect, the present disclosure provides a pharmaceutical composition comprising the molecule as described herein, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0007c] In yet another aspect, there is provided a use of a molecule as described herein, in the manufacture of a medicament for treatment of Huntington's disease (HD).

[0008] In some embodiments, the DNA binding moiety can bind selectively a trinucleotide repeat sequence of for example, *HTT*. The recruiting moiety, linked to the DNA binding moiety, will thus be held in proximity to the target gene; will recruit the regulatory molecule into proximity with the gene; and the regulatory molecule will modulate expression, and therefore counteract the production of defective target gene by direct interaction with the target gene. This mechanism may provide an effective treatment for HD, which is caused by the expression of defective *HTT*, where correction of the expression of the defective target gene thus represents an effective method for the treatment for these diseases.


[0009] The DNA binding moiety comprises a polyamide segment that will bind selectively to the target CAG sequence. Polyamides designed by for example Dervan (U.S. Patent Nos. 9,630,950 and 8,524,899) and others can selectively bind to selected DNA sequences. These polyamides sit in the minor groove of double helical DNA and form hydrogen bonding interactions with the Watson-Crick base pairs. Polyamides that selectively bind to particular DNA sequences can be designed by linking monoamide building blocks according to established chemical rules. One building block is provided for each DNA base pair, with each building block binding noncovalently and selectively to one of the DNA base pairs: A/T, T/A, G/C, and C/G. Following this guideline, trinucleotides bind to molecules with three amide units, i.e. tri-amides. In general, these polyamides can orient in either direction of a DNA sequence.

CLAIMS

WHAT IS CLAIMED IS:

1. A transcription modulator molecule having a first terminus, a second terminus, and an oligomeric backbone moiety, or a pharmaceutically acceptable salt thereof, characterized in that:

a) the first terminus comprises a DNA-binding moiety having the structure of Formula (A-9):



Formula (A-9),

wherein:

W^1 is hydrogen, -C_1-C_6 haloalkyl, or -N=C($N(R^{1e})_2$)$_2$, wherein each R^{1e} is independently hydrogen or optionally substituted C_1-C_3 alkyl;

R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2g}, and R^{2h} are each independently hydrogen, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} aminoalkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_1-C_{20} haloalkyl, optionally substituted C_1-C_{20} hydroxyalkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl; each of which is optionally substituted with one or more R^Z;

each R^{3a} and R^{3b} is independently hydrogen, halogen, C_1-C_6 alkyl, -OR^{3c}, -$NR^{3c}R^{3d}$, or -$NHC(O)R^{3e}$, wherein

R^{3c} and R^{3d} are each independently hydrogen, alkyl, or PEG;

R^{3e} is alkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

or two R^{3a} or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

or one R^{3a} and one R^{3b} together with the atoms to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

each R^Z is independently halogen, -CN, -OH, -OR^{Za}, -N_3, -$NR^{Za}R^{Zb}$, -$CO(O)R^{Zc}$, -$C(O)OR^{Zc}$, -$C(O)NR^{Za}R^{Zb}$, -$NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl,

C_1-C_{10} heteroalkyl, C_3-C_{10} cycloalkyl, 3 to 10-membered heterocycloalkyl, phenyl, or optionally 5 to 10-membered heteroaryl; wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and


R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene by binding a target selected from a member of the BET (bromodomain and extra-terminal) family, CBP/p300, PCAF (P300/CBP-Associated Factor), CECR2 (cat eye syndrome chromosome region candidate 2), BRPF (bromodomain and PHD finger-containing protein), ATAD2/ATAD2B (chromatin remodeling proteins), TRIM24 (Tripartite motif-containing 24), BAZ2 (Bromodomain Adjacent to Zinc finger), or TAF1 (TBP associated factors); and

c) the oligomeric backbone links the first terminus and the second terminus.

2. The molecule of claim 1, or a pharmaceutically acceptable salt thereof, characterized in that at least one of R^{2a}, R^{2b}, R^{2c}, R^{2d}, R^{2e}, R^{2g}, or R^{2h} is not unsubstituted C_1-C_{10} alkyl.

3. The molecule of claim 1, characterized in that the DNA-binding moiety comprises a structure of Formula (I), or a pharmaceutically acceptable salt thereof:



Formula (I),

wherein:

W^1 is hydrogen;

R^{2a}, R^{2c}, R^{2d}, R^{2e}, and R^{2h} are each independently hydrogen, optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} aminoalkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_2-C_{20} heteroalkenyl, optionally substituted C_2-C_{20} heteroalkynyl, optionally substituted C_1-C_{20} haloalkyl, optionally substituted C_1-C_{20} hydroxyalkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl; each of which is optionally substituted with one or more R^Z;

each R^{3b} is independently hydrogen, halogen, C_1-C_6 alkyl, $-OR^{3c}$, $-NR^{3c}R^{3d}$, or $-NHC(O)R^{3e}$, wherein

R^{3c} and R^{3d} are each independently hydrogen, alkyl, or PEG;

R^{3e} is alkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl or 4 to 6-membered heterocycloalkyl;

each R^Z is independently halogen, -CN, -OH, $-OR^{Za}$, $-N_3$, $-NR^{Za}R^{Zb}$, $-CO(O)R^{Zc}$, $-C(O)OR^{Zc}$, $-C(O)NR^{Za}R^{Zb}$, $-NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, C_1-C_{10} heteroalkyl, C_3-C_{10} cycloalkyl, 3 to 10-membered heterocycloalkyl, phenyl, or optionally 5 to 10-membered heteroaryl; wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and

R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl.

4. The molecule of claim 3, or a pharmaceutically acceptable salt thereof, characterized in that R^{2a}, R^{2c}, R^{2d}, R^{2e}, or R^{2h} are each independently an optionally substituted C_1-C_{20} alkyl, optionally substituted C_2-C_{20} alkenyl, optionally substituted C_2-C_{20} alkynyl, optionally substituted C_1-C_{20} haloalkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl, each of which is optionally substituted with one or more R^Z.

5. The molecule of claim 3, or a pharmaceutically acceptable salt thereof, characterized in that R^{2a}, R^{2c}, R^{2d}, R^{2e}, or R^{2h} are each independently optionally substituted C_1-C_{20} alkyl or optionally substituted C_3-C_{10} cycloalkyl.

6. The molecule of claim 3, or a pharmaceutically acceptable salt thereof, characterized in that one or two of R^{2a}, R^{2c}, R^{2d}, R^{2e}, or R^{2h} are independently an optionally substituted C_3-C_{10} cycloalkyl or optionally substituted 3 to 10-membered heterocycloalkyl; and the remaining of R^{2a}, R^{2c}, R^{2d}, R^{2e}, or R^{2h} are an optionally substituted C_1-C_{20} alkyl.


7. The molecule of any one of claims 2 to 6, or a pharmaceutically acceptable salt thereof, characterized in that each R^Z is independently halogen, -CN, -OH, $-OR^{Za}$, $-N_3$, $-NR^{Za}R^{Zb}$, C_1-C_{10} alkyl, C_1-C_{10} haloalkyl, or C_3-C_6 cycloalkyl.

8. The molecule of any one of claims 2 to 7, or a pharmaceutically acceptable salt thereof, characterized in that two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl.

9. The molecule of any one of claims 2 to 7, or a pharmaceutically acceptable salt thereof, characterized in that each R^{3b} is hydrogen.

10. The molecule of claim 1, characterized in that:


a) the first terminus comprises a DNA-binding moiety having the structure of Formula (II):




Formula (II),

wherein:

T^A is $-Q^A-Q^B$; wherein

Q^A is  ;

Q^B is  ; wherein

R^{2j} is an optionally substituted C_1-C_{20} alkyl, optionally substituted with one or more R^Z;

R^{2k} is an optionally substituted C_1-C_{20} alkyl or optionally substituted, C_3-C_{10} cycloalkyl, each of which is optionally substituted with one or more R^Z;

* is the attachment point of Q^A to Q^B;

** is the attachment point to the oligomeric linker;

W^1 is hydrogen;

R^{2c} and R^{2d} are each independently an optionally substituted C_1-C_{20} alkyl, optionally substituted, C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl, each of which is optionally substituted with one or more R^Z;

each R^{3b} is hydrogen or C_1-C_6 alkyl;

or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl;

each R^Z is independently halogen, -CN, -OH, $-OR^{Za}$, $-N_3$, $-NR^{Za}R^{Zb}$, $-CO(O)R^{Zc}$, $-C(O)OR^{Zc}$, $-C(O)NR^{Za}R^{Zb}$, $-NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, or C_1-C_{10} haloalkyl;

or two R^Z together with the atom(s) to which they are attached form a C_3-C_6 cycloalkyl, wherein R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and

R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;


b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene by binding a target selected from a member of the BET (bromodomain and extra-terminal) family, CBP/p300, PCAF (P300/CBP-Associated

Factor), CECR2 (cat eye syndrome chromosome region candidate 2), BRPF (bromodomain and PHD finger-containing protein), ATAD2/ATAD2B (chromatin remodeling proteins), TRIM24 (Tripartite motif-containing 24), BAZ2 (Bromodomain Adjacent to Zinc finger), or TAF1 (TBP associated factors); and

c) the oligomeric backbone links the first terminus and the second terminus.

11. The molecule of claim 1, characterized in that:

a) the first terminus comprises a DNA-binding moiety having the structure of Formula (III):




Formula (III),

wherein:

T^B is $-S^1-Q^L$;

S^1 is $–C(O)NH(CH_2)_2-$; wherein

Q^L is  ; wherein

R^{2m} is an optionally substituted C_1-C_{20} alkyl which is optionally substituted with one or more R^Z;

** is the attachment point to the oligomeric linker;

R^{2c} is an unsubstituted C_1-C_6 alkyl;

R^{2d} and R^{2e} are each independently an optionally substituted C_1-C_{20} alkyl, optionally substituted C_3-C_{10} cycloalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl, each of which is optionally substituted with one or more R^Z;

each R^{3b} is hydrogen or C_1-C_6 alkyl;

or two R^{3b} together with the atom to which they are attached form a C_3-C_6 cycloalkyl;

each R^Z is independently halogen, -CN, -OH, $-OR^{Za}$, $-N_3$, $-NR^{Za}R^{Zb}$, $-CO(O)R^{Zc}$, $-C(O)OR^{Zc}$, $-C(O)NR^{Za}R^{Zb}$, $-NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, or C_1-C_{10} haloalkyl;

or two R^Z together with the atom(s) to which they are attached form a C_3-C_6 cycloalkyl, wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and


R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene by binding a target selected from a member of the BET (bromodomain and extra-terminal) family, CBP/p300, PCAF (P300/CBP-Associated Factor), CECR2 (cat eye syndrome chromosome region candidate 2), BRPF (bromodomain and PHD finger-containing protein), ATAD2/ATAD2B (chromatin remodeling proteins), TRIM24 (Tripartite motif-containing 24), BAZ2 (Bromodomain Adjacent to Zinc finger), or TAF1 (TBP associated factors); and

c) the oligomeric backbone links the first terminus and the second terminus.

12. The molecule of claim 1, characterized in that:

a) the first terminus comprises a DNA-binding moiety having the structure of Formula (V):




Formula (V),


wherein:


T^E is $-Q^M-Q^N$;

T^F is $-S^3-Q^P$; wherein

S^3 is $–C(O)NH(CH_2)_2-$;

Q^M is  ;

Q^N is  ;

Q^P is  ; wherein

R^{2r}, R^{2rr}, and R^{2s} are each independently an optionally substituted C_1-C_{20} alkyl wherein each is optionally substituted with one or more R^Z;

* is the attachment point of Q^M to Q^N; and

** is the attachment point to the oligomeric linker;

R^{2e} is a C_3-C_{10} cycloalkyl which is optionally substituted with one or more R^Z;

each R^Z is independently halogen, -CN, -OH, -OR^{Za}, -N_3, -$NR^{Za}R^{Zb}$, -$CO(O)R^{Zc}$, -$C(O)OR^{Zc}$, -$C(O)NR^{Za}R^{Zb}$, -$NR^{Za}C(O)R^{Zc}$, C_1-C_{10} alkyl, or C_1-C_{10} haloalkyl;

or two R^Z together with the atom(s) to which they are attached form a C_3-C_6 cycloalkyl, wherein

R^{Za} and R^{Zb} are each independently hydrogen, alkyl, haloalkyl, or PEG; and

R^{Zc} is alkyl, haloalkyl, PEG, cycloalkyl, heterocycloalkyl, or phenyl;

b) the second terminus comprises a protein-binding moiety capable of binding to a regulatory molecule that modulates expression of a gene by binding a target selected from a member of the BET (bromodomain and extra-terminal) family, CBP/p300, PCAF (P300/CBP-Associated Factor), CECR2 (cat eye syndrome chromosome region candidate 2), BRPF (bromodomain and PHD finger-containing protein), ATAD2/ATAD2B (chromatin remodeling proteins), TRIM24 (Tripartite motif-containing 24), BAZ2 (Bromodomain Adjacent to Zinc finger), or TAF1 (TBP associated factors); and

c) the oligomeric backbone links the first terminus and the second terminus.

13. The molecule of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, characterized in that the oligomeric backbone is a linker having a length of less than about 50 Angstroms or wherein the oligomeric backbone is a linker having a length of about 10 to 60 Angstroms.

14. The molecule of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, characterized in that the oligomeric backbone comprises a multimer having 2 to 50 spacing moieties, wherein

each spacing moiety is independently selected from the group consisting of -$((CR^{1b}R^{1b})_x$-$O)_y$-, -$((CR^{1b}R^{1b})_x$-$NR^{1a})_y$-, -$((CR^{1b}R^{1b})_x$-CH=CH-$(CR^{1b}R^{1b})_x$-$O)_y$-, optionally substituted C_1-C_{10} alkyl, optionally substituted C_2-C_{10} alkenyl, optionally substituted C_2-C_{10} alkynyl, optionally substituted C_6-C_{10} arylene, optionally substituted C_3-C_7 cycloalkylene, optionally substituted 5 to 10-membered heteroarylene, optionally substituted 4 to 10-membered heterocycloalkylene, amino acid residue, -O-, -C(O)NR^{1a}-, -NR^{1a}C(O)-, -C(O)-, -NR^{1a}-, -C(O)O-, -S-, -S(O)-, -$S(O)_2$-, -$S(O)_2NR^{1a}$-, -$NR^{1a}S(O)_2$-, and -P(O)OH-, and any combinations thereof; wherein

each x is independently 2-4;


each y is independently 1-10;

each R^{1a} is independently hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, -$S(O)_2$-C_1-C_6 alkyl, -$S(O)_2$-C_1-C_6 haloalkyl, -$S(O)_2$-C_3-C_6 cycloalkyl, or -$S(O)_2N$-$(C_1$-C_6 alkyl$)_2$; and

each R^{1b} is independently hydrogen, halogen, optionally substituted C_1-C_6 alkyl, or optionally substituted C_1-C_6 haloalkyl.

15. The molecule of claim 14, or a pharmaceutically acceptable salt thereof, characterized in that the oligomeric backbone comprises a multimer having 2 to 50 spacing moieties, wherein each spacing moiety is independently selected from the group consisting of $-((CH_2)_x-O)_y-$, $-((CH_2)_x-NH)_y-$, -O-, -C(O)NH-, -NH-, and any combinations thereof.

16. The molecule of any of claims 1 to 15, characterized in that (i) the second terminus comprises the structure of Formula (4-A), or a pharmaceutically acceptable salt thereof:



Formula (4-A),

wherein:

Ring D is absent, phenyl, or 5 to 6-membered heteroaryl;

X^9 and X^{10} are each independently C or N, wherein one of X^9 or X^{10} is N;

L^2 is absent, optionally substituted alkylene, -O-, or $-NR^D-$, wherein R^D is hydrogen or optionally substituted C_1-C_3 alkyl;

R^{18} is an optionally substituted 5 to 6-membered heteroaryl;

R^{19} is an optionally substituted C_3-C_8 cycloalkyl or optionally substituted 4 to 7-membered heteroaryl;


each R^{20} is independently hydrogen, halogen, -CN, $-NO_2$, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, or optionally substituted C_1-C_6 hydroxyalkyl;

x_3 is an integer from 1-3; and

y_4 is an integer from 1-4;

wherein the attachment to the linker is at either R^{19} or at one of R^{20}; or

(ii) the second terminus comprises the structure of Formula (7-A), or a pharmaceutically acceptable salt thereof:



Formula (7-A),

wherein:

A^3 is -O-, -NH-, or $-CH_2-$;

Z^2 is CH or N;

W is O or S;

each R^{31} is independently hydrogen, halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_1-C_{10} hydroxyalkyl,

optionally substituted C_2-C_{10} alkenyl, optionally substituted C_2-C_{10} alkynyl, optionally substituted C_3-C_8 cycloalkyl, or optionally substituted 3 to 8-membered heterocycloalkyl;

or two R^{31} together with the atoms to which they are attached join together to form an optionally substituted C_5-C_8 cycloalkyl or optionally substituted 5 to 8-membered heterocycloalkyl;

R^{32} is hydrogen or optionally substituted C_1-C_{10} alkyl;


R^{32a} is hydrogen or optionally substituted C_1-C_{10} alkyl;

R^{33} is hydrogen, halogen, -OH, -CN, -NO_2, -NH_2, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, or optionally substituted C_1-C_{10} hydroxyalkyl; and

q_6 is 0-4;

wherein Formula (7-A) is attached to the linker is at R^{32a} or at one of R^{31}; or

(iii) the second terminus comprises the structure of Formula (2-A), or a pharmaceutically acceptable salt thereof:



Formula (2-A),

wherein:

Ring A is an optionally substituted aryl or optionally substituted 5 to 6-membered heteroaryl;

Ring B is absent or an optionally substituted 6-membered monocyclic aryl or heteroaryl;

D is C or N;

E is O or N;

Y_A is -NH- or -O-;

R^5 is hydrogen or C_1-C_6 alkyl;

R^6 is selected from hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, and optionally substituted C_1-C_6 hydroxyalkyl;


R^7 is selected from hydrogen, halogen, -NO_2, -CN, optionally substituted aryl, optionally substituted C_1-C_{20} alkyl, optionally substituted C_1-C_{20} heteroalkyl, optionally substituted C_1-C_6 haloalkyl, and optionally substituted C_1-C_6 hydroxyalkyl;

or R^7 is -$NR^{7A}R^{7B}$, wherein

R^{7A} and R^{7B} are each independently hydrogen, optionally substituted C_1-C_{20} alkyl, or optionally substituted C_1-C_{20} heteroalkyl; and

x_1 is an integer from 1-6; or

(iv) the second terminus comprises the structure of Formula (3-A), or a pharmaceutically acceptable salt thereof:



Formula (3-A),

wherein:

Y_B is -CH_2NH-, -CH_2O-, -NH-, or -O-;

R^{11A} and R^{11B} are each independently hydrogen, or optionally substituted C_1-C_6 alkyl;

R^{12} is hydrogen, halogen, -OH, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, or optionally substituted C_1-C_6 hydroxyalkyl;

R^{14} and R^{15} are each independently hydrogen, halogen, -CN, -NO_2, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, or optionally substituted C_1-C_6 hydroxyalkyl;

or R^{14} is -NR^AR^B;

R^{16} is optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted C_2-C_6 alkenyl, optionally substituted C_2-C_6 alkynyl, optionally substituted C_1-C_6 hydroxyalkyl, -S(O)(=NH)R^A, -SO_2R^A, or -$NHSO_2R^A$;


R^{YA} is hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 haloalkyl, or optionally substituted 5-6-membered monocyclic aryl or heteroaryl;

each R^A and R^B is independently hydrogen, optionally substituted C_1-C_6 alkyl, optionally substituted C_1-C_6 heteroalkyl, optionally substituted C_1-C_6 haloalkyl, optionally substituted C_1-C_6 hydroxyalkyl, optionally substituted C_3-C_6 cycloalkyl, 4 to 6-membered heterocycloalkyl, or optionally substituted 4 to 6-membered heteroalkyl; and

y_1 is 1-3;

wherein the attachment to the linker is at either R^{14} or at R^{YA}; or

(v) the second terminus comprises the structure of Formula (3-B), or a pharmaceutically acceptable salt thereof:



Formula (3-B),

wherein:

Ring C is absent, optionally substituted 5 to 6-membered monocyclic aryl or heteroaryl or 4 to 8-membered heterocycle;

Y_B is -NH-, -CH_2NH-, -CH_2O-, or -O-;

R^{11A} and R^{11B} are each independently hydrogen or optionally substituted C_1-C_6 alkyl;


R^{12} is hydrogen, optionally substituted C_1-C_6 alkyl, $C(O)R^A$, or $C(O)NR^AR^B$; wherein

each R^A and R^B is independently hydrogen, optionally substituted C_1-C_6 alkyl, or optionally substituted C_1-C_6 heteroalkyl;

R^{13} is hydrogen, substituted aryl, substituted heteroaryl, or substituted oxydibenzene; and

y_2 is an integer from 0-2; or

((vi) the second terminus comprises the structure of Formula (13-A), or a pharmaceutically acceptable salt thereof:



Formula (13-A),

wherein:

Ring J is absent or optionally substituted 5 to 6-membered heteroaryl;

R^{41} is optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_8 cycloalkyl, $-C(O)R^{41a}$, -C(O)-, or $-C(O)NR^{41a}R^{41b}$, wherein

R^{41a} and R^{41b} are each independently optionally substituted C_1-C_{10} alkyl or optionally substituted C_3-C_8 cycloalkyl;

R^{42} is an optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_3-C_8 cycloalkyl, or optionally substituted 3 to 8 membered heterocycloalkyl;

R^{43} is hydrogen or optionally substituted C_1-C_{10} alkyl;

each R^{44} is independently hydrogen, halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, C_1-C_{10} hydroxyalkyl, optionally substituted C_2-C_{10} alkenyl, optionally substituted C_2-C_{10} alkynyl, optionally substituted C_3-C_8-cycloalkyl, or optionally substituted 3 to 8-membered heterocycloalkyl; or


R^{43} and one of R^{44} together with the atoms to which they are attached form an optionally substituted 5 to 8-membered heterocycloalkyl;

p_{12} is 1-4; and

q_3 is 0 or 1;

wherein Formula (13-A) is connected to the linker at Ring J, R^{41}, or R^{42}; or

(vii) the second terminus comprises the structure of Formula (14-A), or a pharmaceutically acceptable salt thereof:



Formula (14-A),

wherein:

Ring K is a 5 to 6-membered heterocycloalkyl;

A^5 is absent, CH_2, -NH-, or -O-;

L^4 is alkylene or heteroalkylene;

each R^{45} is independently halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_1-C_{10} heteroalkyl, optionally substituted C_1-C_{10} hydroxyalkyl, optionally substituted C_2-C_{10} alkenyl, optionally substituted C_2-C_{10} alkynyl, optionally substituted C_3-C_8-cycloalkyl, or optionally substituted 3 to 8-membered heterocycloalkyl;

each R^{46} is independently hydrogen, halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_1-C_{10} hydroxyalkyl, optionally substituted C_2-C_{10} alkenyl, optionally substituted C_2-C_{10} alkynyl, optionally substituted C_3-C_8 cycloalkyl, or optionally substituted 3 to 8-membered heterocycloalkyl;

R^{47} is optionally substituted C_1-C_{10} alkyl, $-C(O)R^{47a}$, or $-C(O)-NR^{47a}R^{47b}$, wherein


R^{47a} and R^{47b} are each independently optionally substituted C_1-C_{10} alkyl or optionally substituted C_3-C_8 cycloalkyl;

q_4 is 2-3; and

q_5 is 0-2;

wherein the Formula (14-A) is connected to the linker through Ring K or through one of R^{45}; or

(viii) the second terminus comprises the structure of Formula (15-C), or a pharmaceutically acceptable salt thereof:



Formula (15-C),

wherein:

X is CR^{48} or N;

each R^{48} is hydrogen, halogen, -OH, -CN, $-NO_2$, $-NH_2$, C_1-C_{10} alkyl, C_1-C_{10} haloalkyl, or C_1-C_{10} hydroxyalkyl;


R^{49} and R^{50} are each independently hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_2-C_{10} alkenyl, or optionally substituted C_2-C_{10} alkynyl;

R^{51} is hydrogen, halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_1-C_{10} hydroxyalkyl, optionally substituted C_2-C_{10} alkenyl, or optionally substituted C_2-C_{10} alkynyl;

R^{53} is hydrogen or optionally substituted C_1-C_{10} alkyl; and

p_7 is 1-3; or

(ix) the second terminus comprises the structure of Formula (16-A), or a pharmaceutically acceptable salt thereof:



Formula (16-A),

wherein:

B^5 is -O-, -NH-, or S;

B^6 is N or CH;

R^{54} is optionally substituted aryl or optionally substituted heteroaryl;

each R^{55} is independently halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, optionally substituted C_1-C_{10} heteroalkyl, or optionally substituted C_1-C_{10} hydroxyalkyl;





R^{56} is hydrogen, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, or optionally substituted C_1-C_{10} hydroxyalkyl;




R^{57} is halogen, -OH, -CN, $-NO_2$, $-NH_2$, optionally substituted C_1-C_{10} alkyl, optionally substituted C_1-C_{10} haloalkyl, or optionally substituted C_1-C_{10} hydroxyalkyl;





p_9 is 1-3; and




q_7 is 0-2.




17. The molecule of claim 1, or a pharmaceutically acceptable salt thereof, characterized in that the molecule is selected from following table:




Cpd. No.	Structure
C-1	
C-2	
C-3	
C-4	




C-5	
C-6	
C-7	




C-8	
C-9	
C-10	
C-11	




C-12	
C-13	
C-14	




C-15	
C-16	
C-17	




C-18	
C-19	
C-20	




C-21	
C-22	
C-23	





C-24	
C-25	
C-26	





C-27	
C-28	
C-29	




C-30	
C-31	
C-32	




C-33	
C-34	
C-35	




C-36	
C-37	
C-38	




C-39	
C-40	
C-41	
C-42	




C-43	
C-44	
C-45	
C-46	




C-47	
C-48	
C-49	




C-50	
C-51	
C-52	





C-53	
C-54	
C-55	




C-56	
C-57	
C-58	




C-59	
C-60	
C-61	




C-62	
C-63	
C-64	




C-65	
C-66	
C-67	




C-68	
C-69	
C-70	
C-71	





C-72	
C-73	
C-74	





C-75	
C-76	
C-77	




C-78	
C-79	
C-80	




C-81	
C-82	
C-83	






C-84	
C-85	
C-86	





C-87	
C-88	
C-89	
C-90	




C-91	
C-92	
C-93	
C-94	




C-95	
C-96	
C-97	




C-98	
C-100	
C-101	




C-102	
C-103	
C-104	
C-105	
C-106	




C-107	
C-108	
C-109	
C-110	




C-111	
C-112	
C-113	




C-114	
C-115	
C-116	




C-117	
C-118	
C-119	




C-120	
C-121	
C-122	





C-123	
C-124	
C-125	




C-126	
C-127	
C-128	




C-129	
C-130	
C-131	





C-132	
C-133	
C-134	





C-135	
C-136	
C-137	





C-138	
C-139	
C-140	
C-141	




C-142	
C-143	
C-144	




C-145	
C-146	
C-147	




C-148	
C-149	
C-150	
C-151	





C-152	
C-153	
C-154	
C-155	





C-156	
C-157	
C-158	
C-159	




C-160	
C-161	
C-162	




C-163	
C-164	
C-165	




C-166	
C-167	
C-168	




C-169	
C-170	
C-171	
C-172	





C-173	
C-174	
C-175	
C-176	





C-177	
C-178	
C-179	




C-180	
C-181	
C-182	




C-183	
C-184	
C-185	




C-186	
C-187	
C-188	




C-189	
C-190	
C-191	
C-192	




C-193	
C-194	
C-195	
C-196	





C-197	
C-198	
C-199	




C-200	
C-201	
C-202	




C-203	
C-204	
C-205	




C-206	
C-207	
C-208	




C-209	
C-210	
C-211	




C-212	
C-213	
C-214	
C-215	




C-216	
C-217	
C-218	




C-219	
C-220	
C-221	




C-222	
C-223	
C-224	





C-225	
C-226	
C-227	




C-228	
C-229	
C-230	




C-231	
C-232	
C-233	




C-234	
C-235	
C-236	





C-237	
C-238	
C-239	





C-240	
C-241	
C-242	
C-243	




C-244	
C-245	
C-246	




C-247	
C-248	
C-249	





C-250	
C-251	
C-252	





C-253	
C-254	
C-255	
C-256	





C-257	
C-258	
C-259	
C-260	





C-261	
C-262	
C-263	





C-264	
C-265	
C-266	





C-267	
C-268	
C-269	
C-270	




C-271	
C-272	
C-273	
C-274	




C-275	
C-276	
C-277	
C-278	





C-279	
C-280	
C-281	
C-282	




C-283	
C-284	
C-285	
C-286	




C-287	
C-288	
C-289	
C-290	




C-291	
C-292	
C-293	




C-294	
C-295	
C-296	




C-297	
C-298	
C-299	
C-300	




C-301	
C-302	
C-303	





C-304	
C-305	
C-306	





C-307	
C-308	
C-309	





C-310	
C-311	
C-312	




C-313	
C-314	
C-315	




C-316	
C-317	
C-318	




C-319	
C-320	
C-321	
C-322	




C-323	
C-324	
C-325	
C-326	




C-327	
C-328	
C-329	
C-330	




C-331	
C-332	
C-333	




C-334	
C-335	
C-336	





C-337	
C-338	
C-339	




C-340	
C-341	
C-342	




C-343	
C-344	
C-345	




C-346	
C-347	
C-348	




C-349	
C-350	
C-351	




C-352	
C-353	
C-354	
C-355	




C-356	
C-357	
C-358	




C-359	
C-360	
C-361	




C-362	
C-363	
C-364	




C-365	
C-366	
C-367	




C-368	
C-369	
C-370	




C-371	
C-372	
C-373	




C-374	
C-375	
C-376	





C-377	
C-378	
C-379	




C-380	
C-381	
C-382	



C-383	
C-384	
C-385	

C-386	
C-387	
C-388	


C-389	
C-390	
C-391	


C-392	
C-393	
C-394	
C-395	


C-396	
C-397	
C-398	


C-399	
C-400	


18. A molecule selected from:



,



,



,



,



,



,


,



,


,



,




,




,




,




,





,





,






















,


,


, or


,

or a pharmaceutically acceptable salt thereof.

19. A pharmaceutical composition comprising the molecule of any one of claims 1-18, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

20. Use of a molecule of any one of claims 1-18, in the manufacture of a medicament for treatment of Huntington's disease (HD).